Hsp90 as Potential Treatment for Lung Cancer
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Clinical Pearls:
- Hsp90 is a rational targeted for cancer since a number of oncoproteins depend on the associate of Hsp90 in order to become active.
- The drug ganetespib has now been combined with chemotherapy in randomized trials as a potential treatment option for lung cancer.
- GALAXY-2, a phase III trial, will randomize patients to docetaxel with or without ganetespib.
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
